New combo therapy aims to keep stomach cancer from coming back after surgery
NCT ID NCT06761846
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or gastroesophageal junction cancer from returning. About 70 adults who have had their tumor removed will receive the combination treatment for up to 16 cycles. Researchers will track how long participants remain cancer-free and monitor side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hodpital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can immunotherapy outperform chemo after stomach cancer surgery?
- Could a smartphone program supervised by AI boost recovery after stomach cancer surgery?
- Can stomach cancer surgery also tame diabetes?
- Can a modified stomach bypass speed up recovery in advanced gastric cancer?